DK1466617T3 - Anvendelse af en farmaceutisk sammensætning indeholdende epidermal vækstfaktor (EGF) til forebyggelse af diabetisk fodamputation - Google Patents

Anvendelse af en farmaceutisk sammensætning indeholdende epidermal vækstfaktor (EGF) til forebyggelse af diabetisk fodamputation

Info

Publication number
DK1466617T3
DK1466617T3 DK02796491T DK02796491T DK1466617T3 DK 1466617 T3 DK1466617 T3 DK 1466617T3 DK 02796491 T DK02796491 T DK 02796491T DK 02796491 T DK02796491 T DK 02796491T DK 1466617 T3 DK1466617 T3 DK 1466617T3
Authority
DK
Denmark
Prior art keywords
egf
prevention
pharmaceutical composition
growth factor
composition containing
Prior art date
Application number
DK02796491T
Other languages
Danish (da)
English (en)
Inventor
Acosta Jorge Berlanga
Montequin Jose I Fernandez
Perez Calixto Valdes
Perez Neobalis Franco
Constantin Ingrid Rojas
Milian Hector Santana
Corvea Larissa Chacon
Nieto Gerardo E Guillen
Martinez Luis Herrera
Frias Leonardo Canan-Haden
Perez Haydee Geronimo
Pena Jorge Sotolongo
Original Assignee
Ct Ingenieria Genetica Biotech
Acosta Jorge Berlanga
Fernandez Montequin Jos I
Milian Hector Santana
Corvea Larissa Chacon
Nieto Gerardo E Guillen
Martinez Luis Herrera
Canan Haden Frias Leonardo
Perez Haydee Geronimo
Pena Jorge Sotolongo
Perez Neobalis Franco
Constantin Ingrid Rojas
Perez Calixto Valdes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40239814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1466617(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Ingenieria Genetica Biotech, Acosta Jorge Berlanga, Fernandez Montequin Jos I, Milian Hector Santana, Corvea Larissa Chacon, Nieto Gerardo E Guillen, Martinez Luis Herrera, Canan Haden Frias Leonardo, Perez Haydee Geronimo, Pena Jorge Sotolongo, Perez Neobalis Franco, Constantin Ingrid Rojas, Perez Calixto Valdes filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of DK1466617T3 publication Critical patent/DK1466617T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02796491T 2001-12-20 2002-12-04 Anvendelse af en farmaceutisk sammensætning indeholdende epidermal vækstfaktor (EGF) til forebyggelse af diabetisk fodamputation DK1466617T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20010308A CU23043A1 (es) 2001-12-20 2001-12-20 Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
PCT/CU2002/000011 WO2003053458A1 (es) 2001-12-20 2002-12-04 Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético

Publications (1)

Publication Number Publication Date
DK1466617T3 true DK1466617T3 (da) 2009-06-15

Family

ID=40239814

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02796491T DK1466617T3 (da) 2001-12-20 2002-12-04 Anvendelse af en farmaceutisk sammensætning indeholdende epidermal vækstfaktor (EGF) til forebyggelse af diabetisk fodamputation

Country Status (22)

Country Link
US (2) US7465704B2 (de)
EP (1) EP1466617B1 (de)
JP (1) JP4808378B2 (de)
KR (1) KR100795654B1 (de)
CN (1) CN1306954C (de)
AR (1) AR037824A1 (de)
AT (1) ATE422897T1 (de)
AU (1) AU2002361923B2 (de)
BR (1) BRPI0215214B8 (de)
CA (1) CA2470971C (de)
CU (1) CU23043A1 (de)
DE (1) DE60231248D1 (de)
DK (1) DK1466617T3 (de)
ES (1) ES2322568T3 (de)
HK (1) HK1077740A1 (de)
MX (1) MXPA04005831A (de)
MY (1) MY139214A (de)
PT (1) PT1466617E (de)
RU (1) RU2289424C2 (de)
SI (1) SI1466617T1 (de)
UA (1) UA80813C2 (de)
WO (1) WO2003053458A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1077740A1 (en) * 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
CU23529A1 (es) * 2005-03-02 2010-06-17 Ct Ingenieria Genetica Biotech Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
CU23388B6 (es) * 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CU23526B6 (es) * 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
US8211947B2 (en) * 2008-01-28 2012-07-03 Guillermo Selman-Housein Sosa Composition and method for treating and preventing musculoskeletal and connective tissue disorders
ES2340902B1 (es) 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
CN101496486B (zh) * 2009-03-13 2011-02-16 新疆巴音郭楞蒙古自治州农业科学研究所 一种蘑菇栽培方法
ES2357601B1 (es) 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
ES2468740B1 (es) 2012-11-13 2015-04-01 Consejo Superior De Investigaciones Científicas (Csic) Apósito para cicatrización de heridas comprometidas
EP3035903B1 (de) 2013-08-20 2018-08-22 Anutra Medical, Inc. Spritzenfüllsystem und -verfahren
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
CN104173366A (zh) * 2014-09-14 2014-12-03 陈钏黄 一种三磷酸腺苷二钠在制备治疗糖尿病足药物中的应用
MX2016016339A (es) * 2016-12-09 2018-06-08 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V Composicion coadyuvante de un factor de crecimiento y un neuropeptido para acelerar la cicatrizacion de heridas y la repitelizacion de organos.
WO2019006127A1 (en) * 2017-06-28 2019-01-03 Rutgers, The State University Of New Jersey ORGANOIDS DERIVED FROM A SINGLE RENAL CELL
WO2019006113A1 (en) * 2017-06-28 2019-01-03 Rutgers, The State University Of New Jersey ORGANOIDS DERIVED FROM A SINGLE CEREBRAL CELL
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético
WO2022060178A1 (ko) 2020-09-21 2022-03-24 고려대학교 산학협력단 유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법
KR102581240B1 (ko) 2020-09-21 2023-09-22 고려대학교 산학협력단 유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법
KR20230146379A (ko) 2022-04-12 2023-10-19 고려대학교 산학협력단 마이크로바이옴을 이용하여 당뇨족부궤양 예후를 예측하는 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US4944948A (en) * 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
CA2013770A1 (en) 1989-04-04 1990-10-04 Jack M. Shaw Use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
EP0437577A1 (de) 1989-08-01 1991-07-24 The University Of Michigan Topische verabreichung von in dehydratisierungs-/rehydratisierungsliposomen eingeschlossenen peptiden/proteinen
AU629316B2 (en) 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
EP0564502B1 (de) * 1990-11-27 2002-01-30 The American National Red Cross Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
CN1160582A (zh) * 1996-12-27 1997-10-01 暨南大学生物工程研究所 含有细胞生长因子的皮肤外用组合物
WO2002009738A1 (en) * 2000-07-28 2002-02-07 Murphy Christopher J Transplant media
HK1077740A1 (en) 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
EP1482966B1 (de) 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Verfahren und zusammensetzung zur behandlung von hautwunden mit epidermalem wachstumsfaktor
CN1720989A (zh) 2004-07-15 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种表皮生长因子缓释微球及其制备方法与应用

Also Published As

Publication number Publication date
CN1306954C (zh) 2007-03-28
US7799760B2 (en) 2010-09-21
KR100795654B1 (ko) 2008-01-21
SI1466617T1 (sl) 2009-08-31
DE60231248D1 (de) 2009-04-02
MY139214A (en) 2009-08-28
BR0215214A (pt) 2004-12-07
ATE422897T1 (de) 2009-03-15
CA2470971C (en) 2011-02-01
AU2002361923B2 (en) 2006-02-02
MXPA04005831A (es) 2004-09-13
UA80813C2 (en) 2007-11-12
EP1466617B1 (de) 2009-02-18
EP1466617A1 (de) 2004-10-13
ES2322568T3 (es) 2009-06-23
RU2004122091A (ru) 2005-04-10
CU23043A1 (es) 2005-05-20
JP4808378B2 (ja) 2011-11-02
KR20040094669A (ko) 2004-11-10
HK1077740A1 (en) 2006-02-24
US20050107294A1 (en) 2005-05-19
JP2005516024A (ja) 2005-06-02
AR037824A1 (es) 2004-12-09
AU2002361923A1 (en) 2003-07-09
PT1466617E (pt) 2009-05-20
RU2289424C2 (ru) 2006-12-20
BRPI0215214B8 (pt) 2021-05-25
US20080312139A1 (en) 2008-12-18
WO2003053458A1 (es) 2003-07-03
CN1620308A (zh) 2005-05-25
BRPI0215214B1 (pt) 2017-05-30
US7465704B2 (en) 2008-12-16
CA2470971A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
DK1466617T3 (da) Anvendelse af en farmaceutisk sammensætning indeholdende epidermal vækstfaktor (EGF) til forebyggelse af diabetisk fodamputation
DE60118859D1 (de) Pharmazeutische Zusammensetzung enthaltend Trehalose zur ophthalmischen Verwendung
DK1158992T3 (da) Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer
DK2412368T3 (da) Sammensætning til behandling af ar
DE60221056D1 (de) Verabreichungsform zur Abgabe einer bioaktiven Substanz
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
DK1296656T3 (da) Fremgangsmåde til fremstilling af et præparat
DK1253153T3 (da) Fremgangsmåde til fremstilling af 4"-substituerede-9-deoxo-9a-aza-9a-homoerythromycin-A-derivater
DK1196163T3 (da) Farmaceutiske sammensætninger til behandling af insulinresistens
DK1425001T3 (da) Phenethanolaminderivater til behandling af respiratoriske sygdomme
DE60206889D1 (de) Pharmazeutische formulierung enthaltend bicalutamid
DK1568367T5 (da) Glucokinase påvirkende forbindelser
DE60116352D1 (de) Verwendung von kcnq kaliumkanalagonisten zur herstellung eines arzneimittels zur modulierung der blasenfunktion
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1349580T4 (da) Fremgangsmåde til forbedring af stabiliteten af en farmaceutisk sammensætning
DK1383482T3 (da) Fremgangsmåde til fremstilling af en farmaceutisk lavdoseringssammensætning
DK1461418T3 (da) Fremgangsmåde til fremstilling af 3-o-deacylated-4'-monophosphoryllipid a (3d-mla)
ZA200806112B (en) Use of a topical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
DE60230088D1 (de) Prothetisches Implantat
DE60211183D1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
DE60119354D1 (de) Spritze zur Dentalanästhesie
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DK1150681T3 (da) Anvendelse af en farmaceutisk sammensætning indeholdende desoxypeganin til behandling af nikotinafhængighed
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler